Jyong Biotech Ltd. (MENS)
NASDAQ: MENS · Real-Time Price · USD
2.270
+0.020 (0.89%)
Sep 3, 2026, 4:00 PM EDT - Market closed
Jyong Biotech Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 1.18 | 0.1 | 0.18 | 0.72 | 0.55 |
Short-Term Investments | - | - | - | 0.09 | 1.83 |
Cash & Short-Term Investments | 1.18 | 0.1 | 0.18 | 0.81 | 2.39 |
Cash Growth | 1098.98% | -44.63% | -78.20% | -65.95% | -43.51% |
Receivables | 13.51 | - | - | - | - |
Prepaid Expenses | 0.85 | 0.11 | 0.1 | 0.1 | 0.26 |
Restricted Cash | 0 | 0 | 1.57 | 1.56 | - |
Total Current Assets | 15.54 | 0.21 | 1.84 | 2.46 | 2.65 |
Property, Plant & Equipment | 3.15 | 3.19 | 3.54 | 6 | 6.78 |
Long-Term Deferred Charges | - | 0.93 | 0.72 | 0.28 | - |
Other Long-Term Assets | 2.08 | 2.04 | 2.14 | 0.01 | 0.01 |
Total Assets | 20.78 | 6.37 | 8.25 | 8.75 | 9.43 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0 | 0 | 0 | 0 | 0.05 |
Accrued Expenses | 22.9 | 1.32 | 1.14 | 0.86 | 1.06 |
Short-Term Debt | 7.71 | 7.23 | 7.9 | 7.17 | 4.76 |
Current Portion of Long-Term Debt | 0.57 | 0.06 | 0.08 | 0.48 | 0.18 |
Current Portion of Leases | 0.08 | 0.16 | 0.13 | 0.17 | 0.25 |
Other Current Liabilities | 3.55 | 3.37 | 5.02 | 4.22 | 0 |
Total Current Liabilities | 34.81 | 12.13 | 14.26 | 12.91 | 6.29 |
Long-Term Debt | 10.16 | 10.68 | 8.52 | 6.32 | 6.26 |
Long-Term Leases | 0.03 | 0.02 | 0.07 | 0.12 | 0.35 |
Other Long-Term Liabilities | 0.69 | 20.06 | 19.47 | 19.04 | 19.86 |
Total Liabilities | 45.68 | 42.89 | 42.32 | 38.38 | 32.76 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | 0 | 0 | 0 | 0 |
Additional Paid-In Capital | 28.53 | 11.81 | 11.81 | 11.81 | 11.81 |
Retained Earnings | -37.75 | -33.08 | -30.06 | -25.66 | -19.03 |
Treasury Stock | -16.37 | -16.37 | -16.37 | -16.37 | -16.37 |
Comprehensive Income & Other | 0.68 | 1.12 | 0.55 | 0.59 | 0.27 |
Shareholders' Equity | -24.91 | -36.52 | -34.07 | -29.63 | -23.33 |
Total Liabilities & Equity | 20.78 | 6.37 | 8.25 | 8.75 | 9.43 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 18.55 | 18.14 | 16.69 | 14.25 | 11.79 |
Net Cash (Debt) | -17.37 | -18.04 | -16.51 | -13.44 | -9.4 |
Net Cash Growth | - | - | - | - | - |
Net Cash Per Share | -0.24 | -0.25 | -0.23 | -0.19 | -0.13 |
Filing Date Shares Outstanding | 74.23 | 74.23 | 71.57 | 71.57 | 71.57 |
Total Common Shares Outstanding | 74.23 | 71.57 | 71.57 | 71.57 | 71.57 |
Working Capital | -19.27 | -11.92 | -12.42 | -10.44 | -3.65 |
Book Value Per Share | -0.34 | -0.51 | -0.48 | -0.41 | -0.33 |
Tangible Book Value | -24.91 | -36.52 | -34.07 | -29.63 | -23.33 |
Tangible Book Value Per Share | -0.34 | -0.51 | -0.48 | -0.41 | -0.33 |
Land | 1 | 0.95 | 1.02 | 1.02 | 1.13 |
Buildings | 2.59 | 2.48 | 2.65 | 2.64 | 2.93 |
Machinery | 0.96 | 0.92 | 0.99 | 0.98 | 1.06 |
Construction In Progress | 0.14 | 0.14 | 0.14 | 0.14 | 0.03 |
Leasehold Improvements | 0.15 | 0.14 | 0.15 | 0.15 | 0.07 |